aldosterone has been researched along with Growth Disorders in 11 studies
Growth Disorders: Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In salt-losing congenital adrenal hyperplasia (CAH), treatment with a mineralocorticoid in doses that normalized plasma renin activity (PRA) induced a marked increase in linear growth." | 1.27 | The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. ( Gunzcler, P; Kuhnle, U; Levine, LS; New, MI; Pareira, JA; Rösler, A, 1983) |
| "Three children with a Bartter's syndrome have been investigated: all of them had growth retardation, hypokalemia (less than 3 mmol/l), raised plasma renin activity and urinary prostaglandins (PGE2 and PGF2 alpha) and a decreased sensibility for angiotensin." | 1.26 | [Bartter's syndrome: seven cases in siblings. Hypothesis of mild forms (author's transl)]. ( Bagros, P; Benatre, A; Dray, F; Drucker, J; Grenier, B; Lebranchu, Y; Nivet, H; Rolland, JC, 1980) |
| "Six children with Bartter's syndrome aged 6 years 4 months to 13 years 11 months were treated with indomethacin (1." | 1.26 | [Bartter's syndrome: the long term effects of indomethacin on growth (author's transl)]. ( David, M; Floret, D; Hage, GN; Roux, A; Teyssier, G, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mital, S | 1 |
| Chung, WK | 1 |
| Colan, SD | 1 |
| Sleeper, LA | 1 |
| Manlhiot, C | 1 |
| Arrington, CB | 1 |
| Cnota, JF | 1 |
| Graham, EM | 1 |
| Mitchell, ME | 1 |
| Goldmuntz, E | 1 |
| Li, JS | 1 |
| Levine, JC | 1 |
| Lee, TM | 1 |
| Margossian, R | 1 |
| Hsu, DT | 1 |
| Kuhnle, U | 1 |
| Rösler, A | 1 |
| Pareira, JA | 1 |
| Gunzcler, P | 1 |
| Levine, LS | 1 |
| New, MI | 1 |
| Nivet, H | 1 |
| Rolland, JC | 1 |
| Lebranchu, Y | 1 |
| Dray, F | 1 |
| Benatre, A | 1 |
| Drucker, J | 1 |
| Grenier, B | 1 |
| Bagros, P | 1 |
| Barton, JS | 1 |
| Hindmarsh, PC | 1 |
| Preece, MA | 1 |
| Brook, CG | 1 |
| DiMartino-Nardi, J | 1 |
| Wesoly, S | 1 |
| Schwartz, L | 1 |
| Saenger, P | 1 |
| Floret, D | 1 |
| David, M | 1 |
| Roux, A | 1 |
| Hage, GN | 1 |
| Teyssier, G | 1 |
| Laue, L | 1 |
| Pizzo, PA | 1 |
| Butler, K | 1 |
| Cutler, GB | 1 |
| Bodin, G | 1 |
| Rival, JM | 1 |
| Gillot, F | 1 |
| Kershnar, AK | 1 |
| Roe, TF | 1 |
| Kogut, MD | 1 |
| Ramanathan, K | 1 |
| Gantt, C | 1 |
| Grossman, A | 1 |
| Canale, VC | 1 |
| Steinherz, P | 1 |
| New, M | 1 |
| Erlandson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)[NCT00113087] | Phase 3 | 230 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
B-Type Natriuretic Peptide (BNP) level. (NCT00113087)
Timeframe: Measured just prior to the Glenn surgery
| Intervention | pg/ml (Median) |
|---|---|
| Enalapril | 79 |
| Placebo | 84 |
B-type natriuretic peptide (BNP) level. (NCT00113087)
Timeframe: at the time of the 14 month visit
| Intervention | pg/ml (Median) |
|---|---|
| Enalapril | 25 |
| Placebo | 39 |
Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | percent (of end diastolic volume) (Mean) |
|---|---|
| Enalapril | 59.3 |
| Placebo | 57.9 |
Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | percent (of end diastolic volume) (Mean) |
|---|---|
| Enalapril | 57.9 |
| Placebo | 56.6 |
Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 2.3 |
| Placebo | 2.1 |
Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | ml (Mean) |
|---|---|
| Enalapril | 29.2 |
| Placebo | 30.7 |
Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | ml (Mean) |
|---|---|
| Enalapril | 24.1 |
| Placebo | 23.2 |
Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 1.1 |
| Placebo | 1.3 |
Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -0.55 |
| Placebo | 0.09 |
Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -1.00 |
| Placebo | -0.86 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.48 |
| Placebo | -0.92 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.86 |
| Placebo | -1.31 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Median) |
|---|---|
| Enalapril | -0.60 |
| Placebo | -0.63 |
MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.46 |
| Placebo | -0.82 |
Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | units on a scale (Median) |
|---|---|
| Enalapril | 96.4 |
| Placebo | 96.4 |
"Neurodevelopmental status (PDI):~the Bayley Scales of Infant Development: Psychomotor Development index z-score ." (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -1.29 |
| Placebo | -1.32 |
Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score . (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | -0.26 |
| Placebo | -0.33 |
Number of participants with moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: at age 14 months
| Intervention | participants (Number) |
|---|---|
| Enalapril | 11 |
| Placebo | 22 |
Number of participants with Moderate to severe AV valve regurgitation. (NCT00113087)
Timeframe: just before the pre-Glenn surgery
| Intervention | participants (Number) |
|---|---|
| Enalapril | 20 |
| Placebo | 32 |
Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Just prior to the pre-Glenn surgery
| Intervention | Participants (Number) |
|---|---|
| Enalapril | 53 |
| Placebo | 56 |
Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise. (NCT00113087)
Timeframe: Measured at 14 months of age
| Intervention | participants (Number) |
|---|---|
| Enalapril | 72 |
| Placebo | 77 |
Ventricular filling pressure measured by catherization (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | mmHg (Mean) |
|---|---|
| Enalapril | 10.9 |
| Placebo | 11.1 |
Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | g (Mean) |
|---|---|
| Enalapril | 25.5 |
| Placebo | 28.1 |
Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40 (NCT00113087)
Timeframe: At 14 months of age
| Intervention | g (Mean) |
|---|---|
| Enalapril | 31.4 |
| Placebo | 34.4 |
Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured at 14 months of age
| Intervention | g/ml (Mean) |
|---|---|
| Enalapril | 1.14 |
| Placebo | 1.20 |
Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment. (NCT00113087)
Timeframe: Measured just before the Glenn surgery
| Intervention | g/ml (Mean) |
|---|---|
| Enalapril | 1.15 |
| Placebo | 1.31 |
Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: at 14 months of age
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 2.5 |
| Placebo | 3.1 |
Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment. (NCT00113087)
Timeframe: just before the Glenn surgery
| Intervention | standard deviation (Mean) |
|---|---|
| Enalapril | 4.0 |
| Placebo | 4.9 |
Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values) (NCT00113087)
Timeframe: Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age
| Intervention | standard deviation (Least Squares Mean) |
|---|---|
| Enalapril | -0.62 |
| Placebo | -0.42 |
3 trials available for aldosterone and Growth Disorders
| Article | Year |
|---|---|
Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle.
Topics: Aldosterone; Angiotensins; Cohort Studies; Double-Blind Method; Female; Genotype; Growth Disorders; | 2011 |
Blood pressure and the renin-angiotensin-aldosterone system in children receiving recombinant human growth hormone.
Topics: Aldosterone; Blood Pressure; Body Water; Body Weight; Child; Female; Growth Disorders; Growth Hormon | 1993 |
Lack of clinical evidence of sodium retention in children with idiopathic short stature treated with recombinant growth hormone.
Topics: Aldosterone; Atrial Natriuretic Factor; Body Height; Child; Female; Growth Disorders; Growth Hormone | 1993 |
8 other studies available for aldosterone and Growth Disorders
| Article | Year |
|---|---|
The effects of long-term normalization of sodium balance on linear growth in disorders with aldosterone deficiency.
Topics: 17-alpha-Hydroxyprogesterone; Addison Disease; Adolescent; Adrenal Hyperplasia, Congenital; Aldoster | 1983 |
[Bartter's syndrome: seven cases in siblings. Hypothesis of mild forms (author's transl)].
Topics: Adolescent; Aldosterone; Angiotensin II; Bartter Syndrome; Child; Female; Growth Disorders; Humans; | 1980 |
[Bartter's syndrome: the long term effects of indomethacin on growth (author's transl)].
Topics: Adolescent; Aldosterone; Bartter Syndrome; Body Height; Body Weight; Bone Development; Child; Cycloo | 1979 |
Growth and neuroendocrine dysfunction in children with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adrenocorticotropic Hormone; Aldosterone; Child; Child, Preschoo | 1990 |
[Chronic idiopathic hypokalemia with hyperkaliuria in a very young infant. (Bioclinical and histological study)].
Topics: Aldosterone; Alkalosis; Angiotensin II; Calcium; Chlorides; Diet, Sodium-Restricted; Growth Disorder | 1969 |
Adrenocorticotropic hormone unresponsiveness: report of a girl with excessive growth and review of 16 reported cases.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Adult; Aldosterone; Arginine; Child; Corticoster | 1972 |
Six year follow-up of a child with Bartter syndrome.
Topics: Aldosterone; Alkalosis; Angiotensin II; Biopsy; Blood Pressure; Child, Preschool; Diet Therapy; Fema | 1973 |
Endocrine function in thalassemia major.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adult; Age Determination by Skeleton; Aldost | 1974 |